Fast Five Quiz: How Prepared Are You to Address Chronic Myelogenous Leukemia?

Emmanuel C. Besa, MD


November 11, 2014

The newer BCR/ABL tyrosine kinase inhibitors dasatinib and nilotinib are more potent than imatinib and result in higher rates of early complete cytogenetic response and major molecular response. They also demonstrate significant activity against many resistant mutations but they are not effective against the BCR/ABL/T3151 mutation. Resistance may develop to these newer agents as well.

To read more about the treatment of CML, click here.

Related Resources


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.